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De-regulated c-myc gene expression is associated with many 
human and animal cancers. Myc overexpression promotes the growth 
of blood and lymphatic vessels, which is due in part to induction of 
growth factors including vascular endothelial growth factor (VEGF). We 
determined that the P493-6 human B cell line increases VEGF 
production 10-fold upon Myc overexpression.  Myc overexpression in 
avian B cells similarly resulted in high level VEGF production.  Real-
time RT-PCR analyses showed that Myc did not alter the VEGF mRNA 
content of these cell lines, indicating that a post-transcriptional 
mechanism regulates VEGF production. VEGF mRNA translation was 
examined by RT-PCR analysis of monosome and polysome sucrose 
gradient fractions from Myc-on and Myc-off P493-6 cells.  Myc 
increased VEGF mRNA translation initiation, as VEGF mRNA loading 
onto polysomes increased 14-fold in Myc-on cells, and the number of 
ribosomes loaded per VEGF mRNA increased 3-fold.  This translational 
regulation is specific to VEGF mRNA, as total polysomes show the 
same sucrose gradient profile in Myc-on and Myc-off cells, with no 
change in the percent ribosomes in polysomes, or in the number of 
ribosomes per polysomal mRNA.  Myc stimulates VEGF production by a 
rapamycin- and LY294002-sensitive pathway, which does not involve 
alteration of eIF4E activity. 
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INTRODUCTION 
 Increased expression of the c-Myc transcription factor is a 
common feature of many human cancers, including colon, breast, 
prostate, and lung cancers, as well as leukemias and lymphomas 
(reviewed by (Nesbit et al., 1999)).  Myc overexpression in various cell 
types in mice or chickens rapidly induces tumors which show increased 
cell growth and delayed differentiation (Brandvold et al., 2001; Iritani 
& Eisenman, 1999; Pelengaris et al., 1999). These tumors also feature 
intensive growth of blood vessels at early stages, which could support 
their rapid growth (Brandvold et al., 2000; Pelengaris et al., 1999; 
Ruddell et al., 2003).  Conditioned media from B cell lines 
overexpressing Myc strongly induces endothelial cell proliferation 
(Brandvold et al., 2000), supporting the idea that Myc induces the 
production of vascular growth factors.  Myc overexpression in B cells of 
Eµ-c-myc transgenic mice also induces extensive growth of lymphatic 
sinuses within lymph nodes, which is associated with greatly increased 
lymph flow (Ruddell et al., 2003).  Some or all of these functions may 
contribute to the ability of Myc overexpression to rapidly induce 
tumors. The strong induction of angiogenesis and lymphangiogenesis 
could also contribute to the association of Myc overexpression with 
metastasis and poor prognosis in human cancers (Nesbit et al., 1999). 
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 Myc influences the transcription of a variety of target genes that 
could promote oncogenesis, including genes involved in cell growth 
and metabolism (Coller et al., 2000; Neiman et al., 2001). Myc has 
also been shown to increase VEGF production in several cell types 
(Baudino et al., 2002; Pelengaris et al., 1999; Ruddell et al., 2003).  
For example, Myc-overexpressing B cells show increased VEGF 
production during early stages of lymphomagenesis in Eµ-c-myc mice 
(Ruddell et al., 2003) VEGF promotes angiogenesis and 
lymphangiogenesis (Nagy et al., 2002; Sundberg et al., 2001), so that 
this factor could contribute to Myc induction of vessel growth.  Hypoxia 
and other cellular stresses such as glucose deprivation strongly induce 
VEGF mRNA transcription, and this pathway is thought to be important 
to drive angiogenesis in hypoxic tumors (Satake et al., 1998; Shweiki 
et al., 1992).  The VEGF promoter contains a consensus Myc binding 
site, although thus far there is little evidence that Myc directly induces 
VEGF mRNA transcription (Baudino et al., 2002).  
Myc influences the transcription of genes involved in RNA 
metabolism and protein synthesis (Coller et al., 2000), so that it is 
also possible that Myc influences VEGF production by a post-
transcriptional mechanism.  Previous studies have shown that hypoxia-
induced VEGF production can be augmented by stabilization of VEGF 
mRNA (Levy et al., 1996; Stein et al., 1995).  VEGF production can 
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also be regulated at the translational level.  Overexpression of the 
eIF4E translation initiation factor in Chinese hamster ovary (CHO) cells 
greatly increased VEGF mRNA translation (Kevil et al., 1996). In a 
breast carcinoma cell line, integrin-mediated signaling, and increased 
VEGF mRNA translation on polysomes (Chung et al., 2002). In this 
latter example, the mammalian target of rapamycin (mTOR) kinase 
induced phosphorylation of eIF4E binding protein (4E-BP1), which can 
release eIF4E and increase its translation initiation activity (reviewed 
by (Gingras et al., 2004)).  The mTOR inhibitor rapamycin blocked 4E-
BP1 phosphorylation and VEGF production, indicating that mTOR is an 
important mediator of VEGF production in this cell line. 
 We used a human B cell line featuring a tetracycline-repressible 
c-myc gene (Pajic et al., 2000), to determine whether and how Myc 
influences VEGF expression in B cells. This P493-6 cell line is 
particularly useful because proliferation can also be driven by an 
estrogen-inducible Epstein Barr virus (EBV) EBNA-2 gene (Kempkes et 
al., 1995), so that c-Myc expression can potentially be turned on or off 
without altering proliferation of these cells.  P493-6 cells grown in 
tetracycline do not express detectible Myc, while cells grown in the 
absence of tetracycline express high Myc levels (Pajic et al., 2000). 
This cell line allowed us to determine that Myc overexpression strongly 
induces VEGF production in proliferating B cells.  This potent effect is 
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entirely mediated by an increase in VEGF mRNA translation initiation, 
while VEGF mRNA levels remain constant. 
 
RESULTS 
The P493-6 human B cell line was developed as a model to 
examine the mechanism by which Myc induces VEGF production. This 
cell line was derived by infection of primary human B cells with an 
Epstein Barr virus (EBV) expressing an estrogen-regulated EBNA-2 
gene (Kempkes et al., 1995). These cells were then transfected with a 
plasmid driving tetracycline-repressible c-myc gene expression (Pajic 
et al., 2000).  Myc-on P493-6 cells grown in 1 µM β-estradiol showed 
high Myc expression by immunoblotting, while Myc was not detectable 
in Myc-off cells treated with 1 µM β-estradiol and 100 ng/ml 
tetracycline (Figure 1a).  The endogenous c-myc gene is not expressed 
at detectible levels in estrogen- and tetracycline-treated P493-6 cells.  
VEGF expression in each condition was examined by ELISA assay of 
conditioned media collected from Myc-on and Myc-off P493-6 cells. 
Myc-on B cells produced 10 times as much VEGF compared to Myc-off 
cells, where Myc had been repressed by the use of tetracycline (Figure 
1b). These results indicate that Myc induces VEGF production from 
P493-6 B cells.    
FIG. 1 
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Varying doses of tetracycline were used to modulate Myc 
expression levels in P493-6 cells.  The tetracycline repressor 
expression cassette is quantitatively sensitive to tetracycline dose so 
that Myc expression can be calibrated from zero to a maximum, by 
using decreasing concentrations of tetracycline from 100 down to 0 
ng/ml (Figure 1c). Measurement of VEGF production in conditioned 
media from these cells demonstrated that VEGF production increases 
coordinately with the level of Myc expression (Figure 1d).  This finding 
suggests that Myc influences VEGF production in a dose-dependent 
fashion. 
 Myc can stimulate cell division, which involves altered expression 
of a number of genes (Grandori et al., 2000), so that Myc-induced 
proliferation could potentially mediate the observed increase in VEGF 
production in Myc-on cells. However, cell division in P493-6 cells is 
also driven by estrogen-induced EBNA2 expression (Kempkes et al., 
1995; Pajic et al., 2000), so that tetracycline shutoff of c-Myc 
expression may not influence the cell cycle in these cells. The growth 
of P493-6 cells under Myc-on and Myc-off conditions was compared by 
counting log phase cells over 3 days, which revealed that Myc-on and 
Myc-off cells proliferate at a similar rate, with Myc-on cells dividing 
somewhat faster (Figure 2a).  Cell cycle analysis by flow cytometry 
confirmed that cell cycle phases are similar in Myc-on and Myc-off cells 
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(Figure 2b).  These findings indicate that the increase in VEGF 
production in Myc-on cells is not due to cell proliferation, but instead 
reflects some other effect of Myc on these cells. Interestingly, Myc 
overexpression visibly increases the size of these cycling cells (Figure 
2c).  This increase in the size of Myc-on cells is also detected by flow 
cytometric analysis of the forward scatter-height plot (Figure 2d).  
These findings indicate that Myc can increase cell growth in 
proliferating cells. 
FIG. 2 
Myc overexpression does not alter VEGF mRNA levels. 
 c-Myc could induce VEGF production in P493-6 cells by 
increasing VEGF mRNA transcription, as Myc is a transcription factor 
which influences the expression of a variety of genes (Coller et al., 
2000).  This hypothesis was tested by measuring VEGF mRNA levels in 
Myc-on and Myc-off cells by real-time RT-PCR, using GAPDH mRNA 
levels as an internal control.  GAPDH mRNA levels are unaffected by 
Myc expression in P493-6 cells, as determined by Northern blot 
analysis (data not shown, and Figure 7).  Surprisingly, P493-6 cells 
showed similar VEGF mRNA levels whether or not Myc was expressed 
(Figure 3).  Standard RT-PCR and agarose gel electrophoresis 
confirmed that VEGF mRNA levels are the same in Myc-on and Myc-off 
cells (data not shown).  These findings suggest that Myc regulates 
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VEGF production by a post-transcriptional mechanism. Moreover, 
hypoxia or stress effects are not likely to account for Myc induction of 
VEGF, as those responses are primarily mediated by increased VEGF 
mRNA transcription (Satake et al., 1998; Shweiki et al., 1992), and by 
increased VEGF mRNA stability (Levy et al., 1996; Stein et al., 1995). 
FIG. 3 
 The relation of Myc to VEGF production was further investigated 
in P493-6 cells during induction of Myc expression.  Myc expression 
was inactivated in P493-6 cells by adding tetracycline for 48 h, and 
then re-induced following its removal. Conditioned media was collected 
at various times, and VEGF production was measured by ELISA assay. 
Addition of tetracycline to cells resulted in a rapid decline of Myc 
expression, and in the amount of VEGF collected in the media during 
the first 8 h (data not shown). Upon removal of tetracycline, Myc 
expression achieved maximum levels within 8 h (Figure 4a). In 
contrast, the rate of VEGF production increased more slowly, reaching 
maximal production 12-24 h after removal of tetracycline (Figure 4b).  
VEGF mRNA levels did not change during Myc shut-off or re-induction 
as measured by real-time RT-PCR (Figure 4C), in agreement with our 
finding that VEGF mRNA levels are not affected by chronic Myc 
overexpression (Figure 3). These findings are consistent with a 
relatively direct effect of Myc to regulate VEGF production at a post-
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transcriptional level, which operates within a few hours after the onset 
of c-Myc overexpression. 
FIG. 4 
Myc also regulates VEGF production in avian lymphocytes 
 The failure to detect an increase in VEGF mRNA in Myc-on P493-
6 cells was surprising, given the fact that Myc regulates gene 
expression at the transcriptional level. Moreover, most studies of VEGF 
regulation have focused on strong transcriptional induction of VEGF 
mRNA by stresses such as hypoxia (Shweiki et al., 1992). We 
examined additional cell lines to determine how Myc influences VEGF 
production in other situations. The DT40 avian bursal lymphoma cell 
line expresses high c-Myc levels (Figure 5a) under the influence of a 
retrovirus integration upstream of the c-Myc gene (Humphries & Baba, 
1984). Conditioned media collected from DT40 cells contains high 
levels of VEGF detected by ELISA assay (Figure 5b), similar to that 
produced by P493-6 cells (Figure 1a). In contrast, the E3 cell line, a 
bone marrow-derived B cell precursor cell line transformed by an REV 
retrovirus (Lewis et al., 1981) expressed undetectable Myc levels in 20 
µg of cell lysate (Figure 5a), and produced low levels of VEGF (Figure 
5b). Similar findings were obtained using the 1W41 REV-transformed B 
cell line, which also showed background VEGF levels (data not shown). 
The E3 cell line was infected with a replication-competent HB1 
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retrovirus (Enrietto et al., 1983; Smith et al., 1985), which expresses 
a 108 kD gag-v-Myc fusion protein, as well as smaller proteolytic 
products (Figure 5a). These E3 + Myc cells produce high levels of 
VEGF, similar to that produced by DT40 cells (Figure 5b). This study 
demonstrates that Myc overexpression in avian hematopoietic cell lines 
also increases VEGF production.  
FIG. 5 
Measurement of VEGF transcript by real-time RT-PCR showed 
the same VEGF mRNA levels in all 3 cell lines, relative to control 
GAPDH mRNA (Figure 5c). These findings indicate that Myc regulates 
VEGF at a post-transcriptional level in these avian cells, as was 
observed for human P493-6 B cells. The increased production of VEGF 
by the Myc-overexpressing DT40 and E3 + Myc cells correlates with 
the ability of conditioned media from these cells to induce proliferation 
of human microvascular endothelial cells, while that from E3 or 1W41 
cells does not induce endothelial proliferation (Brandvold et al., 2000). 
VEGF is a potent endothelial growth factor (Nagy et al., 2002) so that 
VEGF alone or in concert with other vascular growth factors could 
mediate this angiogenic phenotype. 
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Myc increases VEGF mRNA translation in P493-6 cells 
 Our finding that Myc overexpression does not affect VEGF mRNA 
levels suggests that Myc could induce VEGF protein production by 
increasing VEGF mRNA translation. This hypothesis was investigated 
by measuring the distribution of VEGF mRNA on monosomes and 
polysomes separated by sucrose gradient centrifugation, using P493-6 
cells grown in the presence or absence of tetracycline. Cells were lysed 
in buffer containing 1% PET and 1% DOC detergents to release 
membrane-bound as well as cytoplasmic polysomes (Davies & Abe, 
1995). Sucrose gradient fractions were analyzed by A254 profile as 
illustrated in Figure 6a, which shows similar profiles for Myc-on and 
Myc-off cells, although Myc-off cells display somewhat lower RNA 
content. RNA was purified from each gradient fraction, and subjected 
to real-time RT-PCR assay to determine VEGF mRNA levels. Actin 
mRNA was used as an internal control. Analysis of VEGF mRNA 
distribution normalized to actin mRNA, revealed that VEGF mRNA is 
mainly found in the monosome (≤ 80S) fractions in Myc-off cells 
(Figure 6b). However, in Myc-on cells VEGF mRNA is distributed 
throughout the polysome fractions (>80S), indicating that Myc induces 
VEGF mRNA translation. 
FIG. 6 
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Comparison of the uncorrected VEGF mRNA levels in each 
gradient fraction with those corrected as a VEGF:actin mRNA ratio 
yielded a similar profile (data not shown), indicating that VEGF and 
actin mRNA levels could be directly analyzed. This allowed us to 
calculate the total VEGF mRNA units in each fraction, by multiplying 
the relative VEGF units in each sucrose gradient fraction by their RNA 
content. This analysis confirmed that a significant portion of the VEGF 
mRNA is translated in Myc-on cells, with distribution throughout the 
polysome fractions, while VEGF mRNA is almost entirely associated 
with the untranslated monosome fraction in Myc-off cells (Figure 6c).  
In contrast, actin mRNA distribution in monosomes and polysomes is 
similar in Myc-on and Myc-off cells (Supplementary Figure 1). 
The percent VEGF mRNA in polysomes was calculated by 
comparison of the VEGF mRNA content of the monosomes (≤80S) and 
polysomes (>80S). This measurement shows that 2% of the VEGF 
mRNA is associated with polysomes in Myc-off cells (Table 1). In 
contrast, 28% of the VEGF mRNA is associated with polysomes in Myc-
on cells. Analysis of the loading of ribosomes onto VEGF mRNA also 
identified an increase in VEGF mRNA translation efficiency, from an 
average of 2 ribosomes translating each polysomal mRNA in Myc-off 
cells, to 6 ribosomes per mRNA in Myc-on cells.  By contrast, 
measurement of actin mRNA levels in gradient fractions revealed a 
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two-fold increase in loading onto polysomes in Myc-on cells, while the 
average number of ribosomes translating each actin mRNA, remained 
constant at 6 ribosomes per mRNA (Table 1).  These findings indicate 
that, while Myc modestly increases actin mRNA translation, it has a 
much larger effect over VEGF mRNA translation, by increasing VEGF 
mRNA loading onto polysomes 14-fold, and also by increasing the 
number of ribosomes translating each VEGF mRNA 3-fold. These 
observations also indicate that VEGF mRNA translation initiation is the 
rate-limiting step influenced by Myc in B cells. 
Table 1 
Myc exerts modest effects on total protein synthesis in cycling 
cells 
 Previous studies indicated that Myc overexpression increases 
total protein synthesis in P493-6 cells (Iritani & Eisenman, 1999; 
Schuhmacher et al., 1999), although this effect could also be 
attributed to the ability of Myc to induce proliferation in quiescent 
EBNA 2-off and Myc-off cells (Pajic et al., 2000).  Our analysis of 
polysomes in EBNA 2-expressing Myc-on and Myc-off cells allowed us 
to perform a detailed analysis of the effects of Myc on translation in 
cycling cells.  As Table 2 illustrates, the cellular RNA content 
(consisting mainly of rRNA) increases by about 40% in Myc-on cells.  
Comparison of the RNA yield from monosomes and polysomes showed 
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that Myc-on and Myc-off cells contain the same percentage of 
ribosomes in polysomes. Moreover, the average polysome loading for 
all mRNAs remained constant at 5 ribosomes per polysome on 
average.  This finding that Myc does not influence the percent 
ribosomes in polysomes, or the average number of ribosomes per 
polysome, suggests that Myc does not significantly influence overall 
translational efficiency. In fact, measurement of the rate of protein 
synthesis in Myc-on and Myc-off cells showed a two-fold increase in 
35S methionine incorporation (Table 2). This is in good agreement with 
previous measurements of protein synthesis in untreated Myc-off 
P493-6 cells that are not cycling due to Myc and EBNA-2 shutoff, 
versus estrogen-treated EBNA-2-expressing Myc-on P493-6 cells that 
proliferate continuously (Schuhmacher et al., 1999). Our similar 
finding of a two-fold increase in protein synthesis upon Myc activation 
in cycling P493-6 cells, suggests that the moderate effects of Myc on 
overall translation are independent of the cell cycle. This increment in 
protein synthesis elevates the protein content of Myc-on cells by about 
25% (Table 2), which may support the increase in size of these cells 
(Figure 2c,d).  This modest effect of Myc on total protein synthesis 
suggests that the translation of most cellular mRNAs is not 
significantly altered in Myc-on cells, in contrast to the potent effect of 
Myc to increase VEGF mRNA translation. 
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Table 2 
c-Myc expression in P493-6 cells does not affect the levels or 
activity of translation initiation factor eIF4E 
Increased expression of translation initiation factor eIF4E can 
result in enhanced VEGF mRNA translation (De Benedetti & Harris, 
1999; Kevil et al., 1996). Myc overexpression has been associated 
with increased eIF4E mRNA expression (Rosenwald et al., 1993).  The 
eIF4E gene promoter contains a consensus Myc-binding site (Jones et 
al., 1996), suggesting that Myc could increase VEGF mRNA translation 
by increasing eIF4E levels. However, Northern blot analysis revealed 
only a 1.4-fold increase in eIF4E mRNA levels in Myc-on cells relative 
to control GAPDH mRNA (Figure 7).  eIF4E protein levels were also 
similar in Myc-on and Myc-off cells, as determined by immunoblotting 
(Figure 8a). We also found that Myc does not affect eIF4E mRNA 
abundance in avian DT40 or E3 cells (data not shown).  These findings 
show that the increased VEGF mRNA translation observed in Myc-
overexpressing P493-6 cells is not mediated by increased eIF4E 
expression. 
Fig. 7 
eIF4E activity can be modulated via phosphorylation of serine 
residue 209 by the Mnk1 kinase, which has been associated with cell 
growth (Scheper, 2002; Tuxworth et al., 2004; Waskiewicz et al., 
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1999).  An antibody specific for phosphorylated eIF4E was used to 
show that eIF4E is phosphorylated in Myc-on and Myc-off P493-6 cells 
(Figure 8a).  The Mnk1 kinase is also constitutively phosphorylated in 
Myc-on and Myc-off cells (data not shown).  These findings indicate 
that eIF4E or Mnk1 activity is not directly affected by Myc 
overexpression. 
Fig. 8 
 One other example of VEGF mRNA translational control has been 
identified in the MDA-MB-435 human breast carcinoma cell line, which 
requires VEGF for survival (Chung et al., 2002). Integrin α6β4 
expression in this cell line allows survival in low serum, by increasing 
the translation of VEGF mRNA. This autocrine signalling pathway 
involves activation of the phosphatidylinositol-3 kinase/Akt (PI-3K/Akt) 
pathway, and the associated mTOR-dependent phosphorylation of 4E-
BP1, which releases eIF4E from an inhibitory eIF4E- 4E-BP1 complex 
(Lawrence & Abraham, 1997).  We tested whether 4E-BP1 
phosphorylation status is altered by Myc expression in P493-6 cells.  
We were unable to detect phosphorylated 4E-BP1 in P493-6 Myc-on or 
Myc-off cells by immunoblotting, even though phosphorylated 4E-BP1 
was readily detected in serum–induced 293 cells (Fig 8b).   m7GTP-
sepharose beads were used to purify 4E-BP1 associated with cap-
binding eIF4e (Arsham et al., 2003; Rajasekhar et al., 2003).  
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Immunoblotting with a 4E-BP1 antibody determined that equal 
amounts of 4E-BP1 are associated with eIF4E in Myc-on and Myc-off 
cells (Figure 8b).  Taken together, these findings indicate that mTOR 
phosphorylation of 4E-BP1 does not account for increased VEGF mRNA 
translation initiation in B cells.  
The integrin-induced VEGF mRNA translation observed in MDA-
MB-435 breast carcinoma cells was inhibited by rapamycin and by 
LY294002 (Chung et al., 2002), two inhibitors of the PI3K/Akt pathway 
that act upon the mTOR and PI-3 kinases, respectively.  We tested 
whether these pathways could mediate Myc induction of VEGF mRNA 
translation.  P493-6 cells were treated with tetracycline to shut Myc 
off, and then Myc was induced after tetracycline washout, with or 
without rapamycin or LY294002 treatment for 30 h.  ELISA analysis of 
VEGF secretion into the media showed that rapamycin treatment of 
Myc-on cells blocks induction of VEGF production, so that VEGF levels 
are low and similar to those of Myc-off cells treated continuously with 
tetracycline (Figure 8c).  This was a surprising finding in light of the 
failure of Myc to induce mTOR-mediated 4E-BP1 phosphorylation 
(Figure 8B).  However, rapamycin also inhibits mTOR-mediated S6 
kinase phosphorylation of the S6 ribosomal protein, which could 
potentially affect translation of VEGF mRNA in addition to the 
translation of 5’TOP sequence-containing mRNAs (Jefferies et al., 
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1997).  Immunoblotting using an antibody to phosphorylated S6 
ribosomal protein showed similar phosphorylation levels in Myc-on and 
Myc-off cells (Figure 8d), so that this pathway does not mediate Myc 
induction of VEGF production.  S6 ribosomal protein phosphorylation is 
however strongly inhibited by rapamycin treatment (Figure 8d) 
indicating that this drug is effective in these cells.  As a further control, 
immunoblotting for Myc determined that rapamycin treatment does 
not affect Myc protein expression (Figure 8d).  These findings indicate 
that Myc-induced VEGF production is regulated by a rapamycin-
sensitive pathway, which does not involve phosphorylation of 4EBP-1 
or S6 kinase. 
 The PI-3K inhibitor LY294002 also prevented VEGF production in 
Myc-on P493-6 cells (Figure 8C).  PI-3K phosphorylates and activates 
Akt, which then phosphorylates mTOR to increase kinase activity 
(Vivanco & Sawyers, 2002).  However, Akt phosphorylation was not 
affected by Myc expression in P493-6 cells, indicating that 
phosphorylation of this kinase is not involved in Myc-induced VEGF 
production (Figure 8d).  Akt phosphorylation was also not altered by 
LY294002 treatment of P493-6 cells (Figure 8d), suggesting that PI3-K 
does not regulate Akt phosphorylation in these cells.  The LY294002 
treatment was effective to inhibit kinase activity, as S6 ribosomal 
protein phosphorylation was inhibited at the dose used, while Myc 
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protein expression was unaffected (Figure 8D).  These findings indicate 
that Myc acts on an LY294002-sensitive kinase other than Akt to 
induce VEGF mRNA translation. 
 
DISCUSSION  
 Myc is thought to stimulate protein synthesis by increasing the 
biogenesis of ribosomes and translation factors (Schmidt, 1999). Our 
analysis of the effects of Myc in cycling human P493-6 B cells 
demonstrates that Myc overexpression produces a two-fold increase in 
overall protein synthesis. This effect is comparable to that observed 
during Myc-induced proliferation in quiescent (EBNA 2-off and Myc-off) 
P493-6 cells (Schuhmacher et al., 1999). This increased translation 
supports cell growth, as Myc-on P493-6 cells are visibly larger than 
Myc-off cells, while they proliferate at a similar rate. These findings 
demonstrate that Myc effects on protein synthesis are related to cell 
growth, rather than proliferation.  Overexpression of Myc not only 
enhances translation, but also elevates the RNA content of P493-6 
cells by about 40%. This increase in the ribosome pool could account 
for the modest increase in protein synthesis.  A 2-fold increase in 
protein synthesis and increased cell size was also observed in Myc-
expressing B cells from Eµ-c-myc transgenic mice (Iritani & Eisenman, 
1999), suggesting that Myc performs similar roles in vivo. 
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Myc can enhance the transcription of a number of target genes 
that participate in protein synthesis, including eIF4E and eIF2A (Coller 
et al., 2000; Rosenwald et al., 1993). Elevated levels of eIF4E in 
particular are thought to increase the rate-limiting step of translation 
initiation (De Benedetti & Harris, 1999). However, we found that Myc 
does not significantly change eIF4E mRNA or protein levels, or its 
phosphorylation status in B cells. Moreover, we found that Myc does 
not affect overall translation initiation, the rate-limiting step in protein 
synthesis, as the percent ribosomes in polysomes, and the average 
loading of ribosomes onto polysomal mRNAs, were not altered by Myc 
overexpression. These findings suggest that the major effect of Myc to 
stimulate protein synthesis in P493-6 cells involves a general increase 
in ribosome content, rather than an increase in the rate of translation 
initiation or loading of ribosomes onto polysomes. However, our 
finding that Myc strongly increases the initiation of VEGF mRNA 
translation suggests that Myc could also influence the efficiency of 
translation of a subset of cellular mRNAs.  Shiio etal (Shiio et al., 
2002) used a proteomics approach to show that Myc increases the 
expression of some proteins in fibroblasts without affecting their mRNA 
abundance, supporting the idea that Myc could selectively increase the 
translation of certain mRNAs in addition to VEGF mRNA.  The Ras 
oncogene has also been found to influence the translation of a subset 
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of mRNAs in glioblastoma cells (Rajasekhar et al., 2003), supporting 
the idea that translational control is an important component of 
oncogene function. 
Myc may regulate VEGF expression in a variety of cell types, as 
we found that Myc increases VEGF production in human and avian B 
cells, while others found that Myc increases VEGF levels in 
keratinocytes (Pelengaris et al., 1999) and embryonic stem cells 
(Baudino et al., 2002).  Myc-induced VEGF production from B cells 
appears to be entirely mediated by an increase in VEGF mRNA 
translation initiation.  We also observed enhanced VEGF production by 
murine lymphocytes overexpressing Myc in Eµ-c-myc transgenic mice 
(Ruddell et al., 2003), while VEGF mRNA levels remained constant 
(data not shown), suggesting that Myc also influences VEGF mRNA 
translation in B lymphocytes in vivo. However, the finding that Myc is 
required for VEGF expression at the mRNA level in murine embryonic 
stem cells (Baudino et al., 2002), and the finding that Myc inhibits 
VEGF expression in lung cancer cells (Barr et al., 2000), suggest that 
Myc could regulate VEGF gene expression by more than one 
mechanism. 
 Most studies of VEGF gene regulation have focused on the strong 
effect of hypoxia, glucose deprivation, or other stresses to rapidly 
induce VEGF mRNA transcription (Satake et al., 1998; Shweiki et al., 
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1992). Our observation that Myc expression does not affect VEGF 
mRNA levels indicates that VEGF production is not a result of Myc-
induced stress or hypoxia in B cells.  Moreover, our finding that Myc 
increases VEGF production 10-fold by a translational mechanism 
demonstrates that post-transcriptional mechanisms can exert strong 
effects on VEGF production.  Previous studies identified translational 
regulation of VEGF production by increased expression of eIF4E, or by 
mTOR-mediated 4E-BP1 phosphorylation, which stimulate VEGF mRNA 
translation initiation (Chung et al., 2002; Kevil et al., 1996).  In our 
model of VEGF regulation, Myc does not affect the level of eIF4E 
expression or phosphorylation, or the phosphorylation of 4E-BP1.  
These findings suggest that several mechanisms can influence the 
initiation of VEGF mRNA translation, depending on the cell type 
involved.  
Transcripts whose translation is tightly controlled, such as those 
that encode for regulatory proteins involved in cell growth and 
differentiation, often exhibit complex secondary structures in their 5’ 
untranslated regions (UTR; reviewed by (Gingras et al., 2004)).  This 
makes the conventional ribosome scanning process difficult, so that 
these mRNAs are weakly translated under ordinary circumstances. To 
circumvent this limitation, many of these transcripts feature internal 
ribosome entry sites (IRES) in their 5’ UTRs that can promote 
 24
translation initiation at internal start codons (Hellen & Sarnow, 2001). 
The VEGF mRNA belongs to this group of transcripts, as its 5’ UTR 
contains two IRES elements (Akiri et al., 1998; Huez et al., 1998).  
Alternative initiation of VEGF mRNA transcription produces an mRNA 
with a shorter 5’ UTR truncating one of the IRES elements, which could 
potentially influence VEGF mRNA translation initiation (Akiri et al., 
1998).  A mechanism involving the VEGF IRES could potentially 
explain the specific induction of VEGF mRNA translation by Myc, while 
overall protein synthesis is only modestly stimulated by Myc 
overexpression. 
Myc induction of VEGF production is inhibited by the mTOR 
kinase inhibitor rapamycin, and by the PI3K inhibitor LY294002, 
indicating that a kinase signalling pathway is involved in Myc induction 
of VEGF mRNA translation.  We were surprised to find that this does 
not involve mTOR phosphorylation of 4E-BP1, or phosphorylation of 
Akt, indicating that one or more unknown kinases mediate Myc-
induced VEGF mRNA translation.  Rapamycin exerts additional effects 
to inhibit translation initiation (Gingras et al., 2004), for example 
inhibiting eIF4G phosphorylation, although it is not known how this 
influences translation initiation activity (Raught et al., 2000).  Further 
studies will be required to characterize the rapamycin- and LY294002-
sensitive pathway by which Myc induces VEGF mRNA translation 
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initiation, and to determine whether Myc selectively increases the 
translation of additional mRNAs.  
Myc-induced VEGF expression appears to make important 
contributions to the development of the vasculature during 
embryogenesis (Baudino et al., 2002). Myc -/- embryos die at day 
10.5 after defective formation of the heart and blood vessels, which is 
due at least in part to reduced VEGF expression.  The mechanism by 
which Myc induces VEGF gene expression during embryogenesis has 
not been identified (Baudino et al., 2002).  We found that the initiation 
of VEGF mRNA translation in B cells is dependent on the level of Myc 
expression, and that VEGF secretion is strongly stimulated at high but 
physiological Myc levels.  These findings suggest that fluctuations in 
Myc expression could influence VEGF expression, to modulate vessel 
growth during normal organ growth in embryos or in the adult.  
The level of VEGF production induced by Myc overexpression in B 
cells is similar to that produced by tumor cell lines (Bellamy et al., 
1999), consistent with a role of Myc in tumor angiogenesis. In fact, 
Myc strongly induces growth of blood vessels in vivo at early stages of 
Myc-induced tumor formation in mice and chickens (Brandvold et al., 
2000; Pelengaris et al., 1999; Ruddell et al., 2003).  Myc-induced 
VEGF production could also contribute to the strong angiogenic 
phenotype observed in Myc-associated multiple myeloma and Burkitt’s 
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lymphoma (Vacca A, 1994; Vacca et al., 1999; Willis A.E., 1997), or in 
human solid tumors featuring increased Myc expression (Nesbit et al., 
1999). Further analysis of Myc-regulated VEGF mRNA translation will 
establish the contribution of this pathway to normal development and 
cancer. 
 
MATERIALS AND METHODS 
 
Cell culture 
The human P493-6 cell line was maintained in RPMI 1640 
medium containing 10% tetracycline system-approved fetal calf serum 
(BD Biosciences, Palo Alto, CA), 2 mM L-glutamine, and 1 µM β-
estradiol (Sigma, Saint Louis, MO), as previously described (Pajic et 
al., 2000). For repression of c-Myc, 100 ng/ml tetracycline (Sigma, 
Saint Louis, MO) was added to the culture.  For re-induction of Myc, 
cultures were washed 3 times to remove tetracycline, and were 
incubated in media with β-estradiol. The DT40 and E3 avian B cell lines 
were cultured, and E3 cells were infected with the HB1 retrovirus, as 
previously described (Brandvold et al., 2000). Conditioned media was 
collected from cells washed and resuspended in fresh media at 0.7 x 
106 cells/ml. 
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For cell cycle analysis, 2 x 106 cells were fixed in 70% ethanol, 
and DNA content was determined by a FACScan flow cytometer (BD 
Biosciences, Mountain View, CA), as previously described (Iritani & 
Eisenman, 1999).  The percentage of cells in each phase of the cell 
cycle was calculated by using M-cycle software (Phoenix Flow Systems, 
San Diego, CA). Cell size was assessed by flow cytometry using 
CellQuest software (BD Biosciences). 
For measurement of protein synthesis, P493-6 cells (3 x 106) 
grown in the presence or absence of tetracycline for 72 h, and equal 
numbers of cells were metabolically labeled for 1 h with 0.2 mCi of 
[35S]methionine-cysteine (1175 Ci/mmol) (NEN) in 1 ml of 
methionine-free medium, supplemented with dialyzed 10% 
tetracycline-system approved fetal calf serum.  Samples were 




Cell extract samples containing equal amounts of protein (20 µg) 
were heat denatured in SDS sample buffer containing 100 mM DTT, 
resolved by SDS-PAGE, and transferred to PVDF membranes 
(Immobilon-P, Millipore, Bedford, MA). Membranes were probed with a 
polyclonal antibody raised against the N-terminal half of human c-Myc 
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(a gift from Dr. Robert Eisenman) or with one of the following 
antibodies (Cell Signaling Technology, Beverly, MA): eIF4E, 
phosphorylated eIF4E (Ser209), 4E-BP1, phospho-4E-BP1 (Ser65), 
phospho-Akt (Ser473), phospho-S6 Ribosomal Protein (Ser 235/236), 
or phospho-Mnk1 (Thr197/202), followed by detection with HRP-
labelled secondary antibody and Supersignal West Pico 
ChemiLuminescence reagent (Pierce, Rockford, IL).  Blots were then 
stripped and re-probed with actin antibody (Sigma) to confirm equal 
protein loading. 
For detection of 4E-BP1, m7GTP-conjugated Sepharose beads 
were used to purify eIF4E and 4E-BP1 from the cell lysate, as 
previously described (Arsham et al., 2003). Briefly, cells were lysed in 
an affinity purification buffer and incubated with m7GTP-Sepharose 
beads (Amersham), which were then washed 3 times and resolved by 
SDS PAGE and immunoblotting. 
 
ELISA assay 
VEGF concentrations were measured in conditioned media from 
P493-6 cells using a quantitative sandwich enzyme immunoassay 
(DuoSet human VEGF ELISA kit; R&D Systems Inc., Minneapolis, MN), 
which detects the soluble isoforms of human VEGF (VEGF 165 and 
121). For ELISA detection of avian VEGF, a rabbit antibody was raised 
 29
against chicken VEGF 165. The mRNA encoding the 165-amino acid 
chicken VEGF isoform (Flamme et al., 1995) was reverse-transcribed 
using primers 5’-GAGCGGAAGCCCAATGAAG and 3’-
CGCTGCTCACCGTCTCGG, and then expressed in a pET expression 
plasmid (Novagen, Madison, WI) in BL21-DE3 E. coli (Stratagene, La 
Jolla, CA). The resulting 6xHis-tagged VEGF protein was purified from 
cell pellets by Nickel-NTA chromatography (Qiagen, Valencia, CA), 
renatured by dialysis to remove urea (Christinger et al., 1996), and 
concentrated using Centricon-10k filters (Millipore, Billerica, MA). The 
resulting protein was used to immunize rabbits (R&R Rabbitry, 
Stanwood, WA). Antibody was purified by NH4SO4 precipitation, and by 
passage through a column of E. coli proteins linked to Sepharose 4B 
(Bowers et al., 1996). The purified antibody was then used to capture 
VEGF from chicken cell conditioned media, with detection by the pan-
species VEGF antibody provided in the Duoset ELISA kit.  At least 
three independent conditioned media samples were examined in each 
experiment. 
 
Real-time RT-PCR and Northern blot analysis 
Total RNA was isolated from cells with Trizol (Gibco BRL, 
Rockville, MD) and reverse-transcribed by Moloney Murine Leukemia 
Virus reverse transcriptase, using random hexamer primers (Gibco 
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BRL).  Real-time PCR was performed using the Taqman detection 
protocol in an ABI Prism 7700 thermocycler (Applied Biosystems, 
Foster City, CA).  The results for VEGF real-time RT-PCR assays were 
normalized to those obtained for the corresponding beta-actin or 
GAPDH mRNAs, providing a relative quantitation value.  Actin and 
GAPDH mRNAs showed relatively small variation under the conditions 
tested.  Primers were designed using the Primer ExpressTM program 
(Applied Biosystems) and the following sequences were used: human 
VEGF, forward 5’-GCACCCATGGCAGAAGGA, reverse 5’- 
GCTGCGCTGATAGACATCCA; human beta-actin, forward 5’- 
ATCAAGATCATTGCTCCTCCTGAG, reverse 5’- AGCGAGGCCAGGATGGA; 
human GAPDH, forward 5’-GGTGAAGGTCGGAGTCAACG, reverse 5’-
CACCAGGGCTGCTTTTAACTCT; chicken VEGF, forward 5’- 
GCAGAGCGCGGAGTTGTC, reverse 5’- GTCCACCAGGGTCTCAATTGTC; 
chicken beta-actin, forward 5’- CGAGAGAGAAATTGTGCGTGAC, reverse 
5’- TGACCTGACCATCAGGGAGTT.  Taqman probes were obtained from 
Synthegen (Houston, TX) and the following sequences were used: 
human VEGF, 5’-AACTTCACCACTTCGTGATGATTCTGCCCT; human 
beta-actin, 5’-CCGCCGATCCACACGGAGTACTTG; human GAPDH, 5’-
CCAGGCGCCCAATACGACCAAA; chicken VEGF, 5’-
CAAATTCCTGGAAGTCTACGAACGCAGC; chicken beta-actin, 5’- 
TGCTACGTCGCACTGGATTTCGAGC.  RT-PCR reactions using the 
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primers yielded specific products of the expected size.  A standard 
curve of cDNA was tested in each real time RT-PCR experiment, to 
confirm the dynamic range for quantitation. 
 For Northern blot analysis of eIF4E expression, RNA was probed 
with eIF4E or GAPDH cDNA probes.  Data from four independent 
samples was analyzed by phosphoimaging, and was quantitated using 
ImageQuant software (Molecular Dynamics). 
 
Polysome analysis 
P493-6 cells were grown in the presence or absence of 
tetracycline (100 ng/ml) for 72h. Upon harvesting, cells were treated 
with 100 µg/ml cycloheximide (Sigma, Saint Louise, MO) for 15 min at 
37˚C, washed once with cold PBS containing 100 µg/ml cycloheximide, 
and stored at –70’C.  Aliquots of 2 x 107 cells were lysed with 10-12 
strokes using a loose Dounce homogenizer in 1.25 ml of cold lysis 
buffer (200 mM Tris pH 8.8, 25 mM MgCl2, 150 mM KCl, 2% 
polyoxyethylene 10-tridecy ester (PET), 1% Na deoxycholate (DOC), 5 
mM DTT, 0.5 U/µl RNAsin, 1 mg/ml heparin, 100 µg/ml cycloheximide, 
5 mM EGTA pH 8.0 and 200 mM sucrose), as previously described 
(Davies & Abe, 1995). These conditions allow the dissociation of 
membrane-bound polysomes. The lysates obtained were centrifuged 5 
min at 10,000 g, 4˚C to remove nuclei and the cytoplasmic extracts 
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were layered onto 11 ml 15%-50% sucrose gradients (100 mM KCl, 5 
mM MgCl2, 2 mM DTT, 20 mM HEPES KOH pH 7.4) and centrifuged 1h 
50 min at 36,000 g, 4˚C. Twelve fractions (1 ml each) were collected 
from the top of the gradient using an ISCO fraction collector with 
continuous monitoring of absorbance at 254 nm and placed into tubes 
containing 100 µl of 10% SDS for storage at -80 ˚C. After proteinase K 
digestion, total RNA from each fraction was prepared by phenol-
chloroform extraction and equal aliquots (2 µg) were reverse 
transcribed for use in real-time RT-PCR analysis. 
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Table 1.  Myc increases VEGF mRNA translation initiation in P493-6 cells.  
________________________________________________________________________________ 
 




Percent VEGF mRNA 
In polysomesa   28 +/- 3% 2 +/- 0 % 14 
 
Number of ribosomes 
per VEGF mRNAb  6  2  3 
 
Percent actin mRNA  47 +/- 3% 22 +/- 4 % 2 
in polysomesc 
 
Number of ribosomes   6  6  1 
per actin mRNAd 
___________________________________________________________________________ 
 
a. Calculated by comparing the VEGF mRNA content of monosome and polysome sucrose gradient 
fractions, in 3 experiments. 
b. Determined by measuring the median position of VEGF mRNA distribution across sucrose gradient 
polysome fractions, and identification of the average number of ribosomes per polysome in that median fraction, by 
examination of the A254 polysome profile.  Three experiments were analyzed with similar results. 
c. Calculated by comparing the actin mRNA content of monosome and polysome sucrose gradient fractions. 
d. Determined by measuring the median position of actin mRNA distribution across sucrose gradient 
polysome fractions, and by identification of the average number of ribosomes per polysome in that median fraction. 
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    Myc-ON  Myc-OFF Myc-On/Myc-OFF 
______________________________________________________________________________________ 
 
Total RNA content/cella  10.4 +/- 0.9 pg 7.6 +/- 1.1 pg  1.4 
 
Protein content/cellb  38.7 +/- 2.5 pg 31.3 +/- 3.2 pg  1.2 
 
Protein synthesisc  19.1 x 106 +/-  9.8 x 106 +/-  2.0 
1.8 x 106 cpm 1.9 x 106 cpm   
 
Percent ribosomes 
In polysomesd   33%+/-  3% 35%+/-  3%  1.0 
 
Number of ribosomes    
per mRNAe   5  5   1.0 
 
______________________________________________________________________________________ 
a. Measured by A260 absorbence analysis of RNA purified from equal numbers of cells in 5 experiments.  Standard 
errors are shown. 
b. Measured by Bradford assay of protein content in equal numbers of cells in 7 experiments. 
c. Measured by 35S-methionine-cysteine incorporation in 3 experiments. 
d. Calculated by comparing RNA content of sucrose gradient monosome (<=80S) and polysome (>80S) fractions. 
e. Determined by measuring the median position of RNA content across sucrose gradient polysome fractions, and 
by identification of the average number of ribosomes per polysome in that median fraction. 
 
LEGENDS TO FIGURES 
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Figure 1.  Myc-dependent production of VEGF in P493-6 cells. 
(a) Myc and actin protein expression in P493-6 cells grown in the 
absence (Myc-on) or presence (Myc-off) of tetracycline for 72 h, as 
determined by immunoblotting.  (b) ELISA analysis of media from 
equal numbers of Myc-on cells grown in media, or from Myc-off cells 
treated with tetracycline for 72 h.  Standard errors are shown.  (c)  
Immunoblot expression of Myc protein following 72 h administration of 
tetracycline at decreasing concentrations.  (d)  ELISA assay of the 
media from these cells demonstrates Myc dose-dependent induction of 
VEGF secretion. 
 
Figure 2.   Myc-on cells grow larger while they proliferate at a 
similar rate as Myc-off P493-6 cells. (a)  Cells were seeded at 0.7 
x 106 cells/ml and grown for three days.  Cells were stained with 
Trypan Blue and counted each day.  Standard errors from 3 
experiments are shown.  (b) Cell cycle analysis by flow cytometry of 
PI-stained cells.  The percent cells in each phase of the cell cycle are 
given.  (c) Myc-on cells are larger than Myc-off cells, shown at 400x 




Figure 3.  Myc does not affect VEGF mRNA abundance in P493-6 
cells.  Real-time RT-PCR was performed on equal amounts of total 
RNA from P493-6 cells grown in Myc-on or Myc-off conditions for 3 
days.  Myc expression does not affect the level of VEGF transcript, in 
triplicate assays.  Standard errors are shown for triplicate assays. 
 
Figure 4.  VEGF production increases within hours after Myc 
induction. (a) Myc expression achieves maximum levels within 8 h 
following removal of tetracycline, as determined by immunoblotting.  
(b) Maximal production of VEGF is re-established within 12-24h, as 
determined by ELISA assay.  Cells were incubated with tetracycline for 
48h and then were washed and grown in media plus β-estradiol for 
varying times (Tetracycline Removal).  Control Myc-on cells (No 
Tetracycline) were treated similarly, except that they were not 
incubated with tetracycline.  Conditioned media were collected at 
intervals as indicated.  (c)  Real-time RT-PCR analysis of these cells 
shows similar VEGF mRNA levels, which are not affected by Myc 
expression. 
 
Figure 5.  Myc induces VEGF production in avian hematopoieitic 
cells.  (a)  DT40 B lymphoma cells show high Myc expression, while 
E3 progenitor cells show low Myc expression, as determined by 
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immunoblotting.  E3 + Myc cells infected with HB1 retrovirus show 
increased expression of v-myc-gag fusion proteins.  Twenty 
micrograms of protein were loaded on each gel lane.  (b) Myc-
overexpressing DT40 and E3 + Myc cells show high levels of VEGF 
production, while low Myc E3 cells produce background levels of VEGF, 
as determined by ELISA assay.  Standard errors are shown.  (c)  VEGF 
transcript abundance is the same in high and low Myc cell lines, as 
determined by real-time RT-PCR.  VEGF mRNA data was normalized to 
internal control GAPDH mRNA. 
 
Figure 6.  Myc selectively increases VEGF mRNA translation on 
polysomes.  (a) Representative A254 gradient profiles of lysates from 
equal numbers of Myc-on and Myc-off P493-6 cells.  (b) Distribution of 
VEGF mRNA in each fraction normalized to actin mRNA, as measured 
by real-time RT-PCR assay in three experiments.  Standard errors are 
shown.  (c) Distribution of VEGF mRNA content in each fraction (VEGF 
mRNA units x RNA content per fraction). 
 
Figure 7.  Myc does not affect eIF4E mRNA levels.   eIF4E mRNA 
abundance is similar in Myc-on and Myc-off P493-6 cells, as 
determined by Northern blot analysis.  GAPDH mRNA levels were 
measured as an internal control.  
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Figure 8.   A rapamycin- and LY294002-sensitive signalling 
pathway mediates VEGF production from P493-6 cells.  (a) 
eIF4E protein levels are the same in Myc-on and Myc-off P493-6 cells. 
eIF4E is constitutively phosphorylated in Myc-on and Myc-off cells, as 
determined by immunoblotting with an antibody to phosphorylated 
eIF4E.  (b)  4E-BP1 phosphorylation is undetectable in Myc-on or Myc-
off cells, while serum-induced 293 cells show 4E-BP1 phosphorylation.  
m7GTP affinity purification method captures similar amounts of 4E-BP1 
from equal numbers of Myc-on and Myc-off cells. (c) Rapamycin or 
LY294002 treatment for 30 h prevents Myc induction of VEGF 
production in P493-6 cells, as shown by ELISA analysis.  Standard 
errors are shown.  (d)  Rapamycin or LY294002 treatment during Myc 
induction inhibits S6 ribosomal protein phosphorylation, while Akt 
phosphorylation in not affected, as shown by immunoblotting.  Myc 
expression is also not affected by these drugs. 
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